Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  American Journal of Pathology

• Publication date

  2010-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2353/ajpath.2010.100040PMID 20581060PMCID PMC2913372
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biological impact of freezing Plk1 in its inactive conformation in cancer cells

  2010cited by this paper
• Polo-like kinases: conservation and divergence in their functions and regulation

  2009cited by this paper
• A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53

  2009cited by this paper
• Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.

  2009cited by this paper
• Identification and Validation of a Potent Type II Inhibitor of Inactive Polo‐like Kinase 1

  2009cited by this paper
• Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery

  2008cited by this paper
• Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles.

  2008cited by this paper
• BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

  2007cited by this paper
• Rational combinations of siRNAs targeting Plk1 with breast cancer drugs

  2007cited by this paper
• The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.

  2007cited by this paper
• Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.

  2006cited by this paper
• Targeting polo-like kinase 1 for cancer therapy

  2006cited by this paper
• Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer.

  2006cited by this paper
• Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy.

  2006cited by this paper
• Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer.

  2005cited by this paper
• Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy.

  2005cited by this paper
• Polo-like kinases and oncogenesis

  2005cited by this paper
• Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.

  2005cited by this paper
• Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications

  2005cited by this paper
• Inhibition of Human Chk1 Causes Increased Initiation of DNA Replication, Phosphorylation of ATR Targets, and DNA Breakage

  2005cited by this paper
• Patient-based cross-platform comparison of oligonucleotide microarray expression profiles

  2005cited by this paper
• Progress in the discovery of polo-like kinase inhibitors.

  2005cited by this paper
• ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

  2005cited by this paper
• Polo-like kinases and the orchestration of cell division

  2004cited by this paper
• Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1.

  2004cited by this paper
• Polo-like Kinase-1 Is Required for Bipolar Spindle Formation but Is Dispensable for Anaphase Promoting Complex/Cdc20 Activation and Initiation of Cytokinesis*

  2004cited by this paper
• Ionizing radiation inhibits the PLK cell cycle gene in a G2 checkpoint-dependent manner.

  2004cited by this paper
• Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1

  2003cited by this paper
• Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells

  2003cited by this paper
• Polo‐like kinase 1 (PLK1) is overexpressed in primary colorectal cancers

  2003cited by this paper
• Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer.

  2003cited by this paper
• Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells.

  2002cited by this paper
• Identification of high risk breast-cancer patients by gene expression profiling.

  2002cited by this paper
• Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells

  2002cited by this paper
• Inhibition of Polo-like Kinase-1 by DNA Damage Occurs in an ATM- or ATR-dependent Fashion*

  2001cited by this paper
• PLK (polo‐like kinase), a new prognostic marker for oropharyngeal carcinomas

  2000cited by this paper
• Polo-like kinase-1 is a target of the DNA damage checkpoint

  2000cited by this paper
• Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function.

  2000cited by this paper
• Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck.

  1999cited by this paper
• Polo-like kinases: positive regulators of cell division from start to finish.

  1998cited by this paper
• The Polo‐like kinase Cdc5p and the WD‐repeat protein Cdc20p/fizzy are regulators and substrates of the anaphase promoting complex in Saccharomyces cerevisiae

  1998cited by this paper
• The polo‐like kinase Plx1 is required for M phase exit and destruction of mitotic regulators in Xenopus egg extracts

  1998cited by this paper
• Polo-like kinases: a team that plays throughout mitosis.

  1998cited by this paper
• Pathological features of rectal cancer after preoperative radiochemotherapy

  1997cited by this paper
• Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes

  1996cited by this paper

• Onvansertib inhibits cell proliferation and increases sensitivity to paclitaxel in uterine serous cancer cells.

  2025cites this paper
• A review on synthetic routes and pharmacological applications of thiophene clubbed benzimidazoles

  2025cites this paper
• Network pharmacology insights into the mechanisms of Panax notoginseng saponins in rectal cancer

  2025cites this paper
• Yeast centrosomes act as organizing centers to promote Polo kinase–mediated adaptation to persistent DNA damage

  2025cites this paper
• Onvansertib exhibits anti-proliferative and anti-invasive effects in endometrial cancer

  2025cites this paper
• Polo-like Kinase 1 Predicts Lymph Node Metastasis in Middle Eastern Colorectal Cancer Patients; Its Inhibition Reverses 5-Fu Resistance in Colorectal Cancer Cells

  2024cites this paper
• Polo-like Kinase 1 Expression as a Biomarker in Colorectal Cancer: A Retrospective Two-Center Study

  2024cites this paper
• PLK1 and FoxM1 expressions positively correlate in papillary thyroid carcinoma and their combined inhibition results in synergistic anti‐tumor effects

  2024cites this paper
• Development of MPS1 Inhibitors: Recent Advances and Perspectives.

  2023cites this paper
• Identification of potential functions of polo-like kinase 1 in male reproductive development of the oriental river prawn (Macrobrachium nipponense) by RNA interference analysis

  2022cites this paper
• AURKA and PLK1 inhibition selectively and synergistically block cell cycle progression in diffuse midline glioma

  2022cites this paper
• Present and Future Perspective on PLK1 Inhibition in Cancer Treatment

  2022cites this paper
• Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma

  2021cites this paper
• Nanotechnology Approaches for Colorectal Cancer Diagnosis and Therapy

  2021cites this paper
• Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer

  2021cites this paper
• Non-mitotic functions of polo-like kinases in cancer cells.

  2020cites this paper
• A novel mechanism of HIF2-dependent PLK1-mediated metastasis and drug resistance of clear cell Renal Cell Carcinoma

  2020cites this paper
• The Prognostic Relevance of the Proliferation Markers Ki-67 and Plk1 in Early-Stage Ovarian Cancer Patients With Serous, Low-Grade Carcinoma Based on mRNA and Protein Expression

  2020cites this paper
• Molecular biomarkers: multiple roles in radiotherapy

  2020cites this paper
• Mitotic Exit of Ovarian ancer Cells by Pharmaceutical hibition of the Anaphase-romoting Complex Reduces hromosomal Instability

  2019cites this paper
• Centrosome Amplification and Tumorigenesis: Cause or Effect?

  2019cites this paper
• Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability

  2019cites this paper
• Anti-proliferative bioactivity against HT-29 colon cancer cells of a withanolides-rich extract from golden berry (Physalis peruviana L.) calyx investigated by Foodomics

  2019cites this paper
• Clinicopathological and prognostic implications of polo-like kinase 1 expression in colorectal cancer: A systematic review and meta-analysis.

  2019cites this paper
• Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status

  2019cites this paper
• Immunohistochemical expression of polo-like kinase 1 in oral squamous cell carcinoma and oral submucous fibrosis

  2018cites this paper
• PLK1 has tumor-suppressive potential in APC-truncated colon cancer cells

  2018cites this paper
• BI2536 induces mitotic catastrophe and radiosensitization in human oral cancer cells

  2018cites this paper
• Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.

  2017cites this paper
• Polo-like kinase 1 (Plk1) overexpression enhances ionizing radiation-induced cancer formation in mice

  2017cites this paper
• Plk1 Phosphorylation of Mre11 Antagonizes the DNA Damage Response.

  2017cites this paper
• Spindle Assembly Checkpoint as a Potential Target in Colorectal Cancer: Current Status and Future Perspectives

  2017cites this paper
• Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells.

  2017cites this paper
• The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis

  2017cites this paper
• Mécanisme de contrôle de l'entrée en mitose par Polo-like kinase 1 (PlK1)

  2017cites this paper
• Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer

  2017cites this paper
• Theoretical studies on benzimidazole and imidazo[1,2-a]pyridine derivatives as Polo-like kinase 1 (Plk1) inhibitors: Pharmacophore modeling, atom-based 3D-QSAR and molecular docking approach

  2017cites this paper
• Exploration of Mutation and DNA Methylation of Polo-Like Kinase 1 (PLK1) in Colorectal Cancer

  2017cites this paper
• Cell cycle regulation and DNA damage response : a record of polo-like kinase 1 activity

  2017cites this paper
• Molecular interactions of polo-like kinase 1 in human cancers

  2016cites this paper
• Nanotechnologies for the treatment of colon cancer: From old drugs to new hope.

  2016cites this paper
• FOXC2 regulates the G2/M transition of stem cell-rich breast cancer cells and sensitizes them to PLK1 inhibition

  2016cites this paper
• Decreased PLK1 expression denotes therapy resistance and unfavourable disease-free survival in rectal cancer patients receiving neoadjuvant chemoradiotherapy.

  2016cites this paper
• Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications

  2016cites this paper
• Predictive Biomarkers of Radiation Sensitivity in Rectal Cancer

  2016cites this paper
• Polo-like kinase 1 mediates BRCA1 phosphorylation and recruitment at DNA double-strand breaks

  2016cites this paper
• PLK1, A Potential Target for Cancer Therapy

  2016cites this paper
• PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors.

  2016cites this paper
• BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments

  2015cites this paper
• The role of recent nanotechnology in enhancing the efficacy of radiation therapy.

  2015cites this paper
• Upregulated Polo-Like Kinase 1 Expression Correlates with Inferior Survival Outcomes in Rectal Cancer

  2015influential citation
• Survival of primary, but not of cancer cells after combined Plk1-HDAC inhibition

  2015cites this paper
• Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

  2015influential citation
• Polo-Like Kinases in Colorectal Cancer: Potential for Targeted Therapy

  2015cites this paper
• Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas.

  2014cites this paper
• Vanillin-derived antiproliferative compounds influence Plk1 activity.

  2014cites this paper
• PLK1-inhibition can cause radiosensitization or radioresistance dependent on the treatment schedule.

  2014cites this paper
• Combinatorial inhibition of Plk1 and PKCβ in cancer cells with different p53 status

  2014cites this paper
• Integrated Analysis of Copy Number Variation and Genome-Wide Expression Profiling in Colorectal Cancer Tissues

  2014cites this paper
• Current assessment of polo-like kinases as anti-tumor drug targets

  2014cites this paper
• Inhibition of Polo-Like Kinase 1 Induces Cell Cycle Arrest and Sensitizes Glioblastoma Cells to Ionizing Radiation

  2013cites this paper
• Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation.

  2013cites this paper
• In vitro targeting of Polo-like kinase 1 in bladder carcinoma

  2013cites this paper
• Identification of predictive biomarkers of resistance to radiotherapy in rectal cancer

  2013cites this paper
• hPEBP4 as a predictive marker for the pathological response of rectal cancer to preoperative radiotherapy

  2013cites this paper
• High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.

  2013cites this paper
• Impact of PLK-1 silencing on endothelial cells and cancer cells of diverse histological origin.

  2013cites this paper
• Inhibition of PLK1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitization

  2013cites this paper
• Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation.

  2013cites this paper
• Cancer signaling networks and their implications for personalized medicine

  2013cites this paper
• Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer.

  2012cites this paper
• Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer.

  2012cites this paper
• Polo-like kinase 1 as target for cancer therapy

  2012cites this paper
• Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma.

  2012cites this paper
• Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain

  2011cites this paper
• Efficient Inhibition of Human Colorectal Carcinoma Growth by RNA Interference Targeting Polo-Like Kinase 1 In Vitro and In Vivo

  2011cites this paper
• Fate of primary cells at the G1/S boundary after polo-like kinase 1 inhibition by SBE13

  2011cites this paper
• verexpression of polo-like kinase 1 and its clinical significance in human on-small cell lung cancer

  2011cites this paper
• Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis

  2011cites this paper